Ocular stays the course in allergic conjunctivitis

Ocular Therapeutix Inc. (NASDAQ:OCUL) said it will continue to pursue development of OTX-DP to treat allergic conjunctivitis after the molecule met one of two primary endpoints in a Phase II trial.

On one endpoint, patients treated with the sustained-release dexamethasone showed a mean improvement of 0.5 units vs. placebo on a five-point scale measuring ocular itching and conjunctival redness at all three time points assessed on day 14 of treatment. On the other, the treatment group did not show a mean difference of 1 unit vs. placebo for either itching or redness at two of three time points on the same day. ...